The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells
Open accessAbstract
Paclitaxel (PTX) is a gold standard chemotherapeutic agent for breast, ovarian, pancreatic and non-small cell lung carcinoma. However, in clinical use PTX can have adverse side effects or inadequate pharmacodynamic parameters, limiting its use. Nanotechnology is often employed to reduce the therapeutic dosage required for effective therapy, while also minimizing the systemic side effects of chemotherapy drugs. However, there is no nano formulation of paclitaxel with chemosensitization motifs built in. With this objective, we screened eleven pharmaceutical excipients to develop an alternative paclitaxel nanoformulation using a self-assembly method. Based on the screening results, we observed tannic acid possesses unique properties to produce a paclitaxel nanoformulation, i.e., tannic acid-paclitaxel (TAP). This stable TAP nanoformulation, referred to as TAP nanoparticles (TAP NPs), showed a spherical shape of 102.22±14.05 nm and negative zeta potential of −8.85±0.44 mV. The presence of PTX in TAP NPs was confirmed by Fourier Transform Infrared (FTIR) spectra, thermogravimetric analyzer (TGA) scans, and X-ray diffraction (XRD). Encapsulation efficiency of PTX in TAP NPs was determined to be > 96.49±0.43 %. Intracellular drug uptake of plain drug PTX on breast cancer cells (MDA-MB-231) shows more or less constant drug concentration from 2–6 hours, suggesting drug efflux by the P-gp transporters, over TAP NPs, in which PTX uptake was more than 95.52+11.01% in 6 hours, as analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Various biological assays such as proliferation, clonogenic formation, invasion, and migration confirm superior anticancer effects of TAP NPs over plain PTX at all tested concentrations. P-gp expression Rhodamine-123 (RH123), beta-tubulin stabilization, Western blot, and microarray analysis further confirm the improved therapeutic potential of TAP NPs. These results suggest that the TAP nanoformulation provides an important reference for developing a therapeutic nanoformulation affording pronounced, enhanced effects in breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Cited by
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Tannic acid-based metal phenolic networks for bio-applications: a review
Guo, Z., Xie, W., Lu, J., Guo, X., Xu, J., Xu, W., Chi, Y., Takuya, N., Wu, H., & Zhao, L. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00383f · Cited by 375
A Compressive Review about Taxol®: History and Future Challenges
Gallego-Jara, J., Lozano-Terol, G., Sola-Martínez, R. A., Cánovas-Díaz, M., & de Diego Puente, T. (2020) · Molecules · doi:10.3390/molecules25245986 · Cited by 344
Pharmacological effects and mechanisms of tannic acid
Jing, W., Xiaolan, C., Yu, C., Feng, Q., & Haifeng, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113561 · Cited by 299
Metadata
- Authors
- Chowdhury, P., Nagesh, P. K. B., Hatami, E., Wagh, S., Dan, N., Tripathi, M. K., Khan, S., Hafeez, B. B., Meibohm, B., Chauhan, S. C., Jaggi, M., & Yallapu, M. M.
- Venue
- Journal of Colloid and Interface Science
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 535
- Pages
- 133-148
- ISSN
- 0021-9797 (ISSN-L)
- OpenAlex
- W2892565790
- Cited by
- 162
- References
- 1
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. https://app.cochat.ai/papers/10.1016/j.jcis.2018.09.072
- The paper
- Chowdhury, P., Nagesh, P. K. B., Hatami, E., Wagh, S., Dan, N., Tripathi, M. K., Khan, S., Hafeez, B. B., Meibohm, B., Chauhan, S. C., Jaggi, M., & Yallapu, M. M. (2019). Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. Journal of Colloid and Interface Science. https://doi.org/10.1016/j.jcis.2018.09.072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.